Life sciences companies in Cambridge no longer need to rely on London-based advisers to scale globally — the expertise exists within the region. Kim Wedral, Cambridge-based partner at law firm Winston Taylor, explains how.
Cambridge has become one of Europe’s most active life sciences clusters, and the story behind that success is not just scientific.
It is also about how companies navigate the journey from university spin-out to international exit, and the advisers who help them do so without ever needing to leave the region.
The companies that do this well are usually those that start preparing for each stage of that journey from the outset, rather than only once the next milestone is in view.
Getting the foundations right at formation
The most damaging mistakes tend to happen well before a company is thinking about institutional investment.
Founders frequently underestimate the importance of getting cap tables, founder agreements and early consultancy arrangements right from day one.
Loose or informal arrangements with early collaborators, unclear allocation of equity between founders, and a failure to properly document assignment of intellectual property from academic co-founders are among the most common issues we see.
This is a particularly recurring issue for life sciences spin-outs, given how many of them emerge directly from university research groups. These are not merely administrative details.
They surface during due diligence, and they can materially affect valuation, slow down a funding round, or in the worst cases cause an investor to walk away.
Addressing them properly at formation, with good legal advice, is one of the cheapest forms of insurance a spin-out can buy.
Building fundability from the outset
Investors backing early-stage life sciences companies are increasingly prioritising strong translational data, a credible route to clinical or commercial proof points, and management teams who understand what institutional capital will expect at each subsequent round.
Deal structures are evolving accordingly. We are seeing more staged investment tied to milestones, greater use of convertible instruments to bridge early rounds, and closer attention to founder and investor rights being aligned from the outset, rather than renegotiated under pressure later.
For life sciences companies in particular, where product timelines are long and capital-intensive, this discipline matters more than in most sectors. For founders, the message is consistent: fundability is built early, not retrofitted at Series A.
IP and labour as valuable assets
Intellectual property is frequently the single most valuable asset a life sciences spin-out holds, yet it is too often treated as a compliance exercise rather than a commercial strategy.
Patent strategy should be considered from day one: what to protect, when to file, and how filings align with the company’s commercial roadmap and target markets.
Poorly structured IP, whether through gaps in the chain of title, inconsistent inventor assignments, or filings that do not reflect commercial reality, can significantly weaken a company’s negotiating position in a funding round or, later, in an exit process.
The same is true of licensing negotiations, which for many life sciences companies are how IP value is first realised, well before any exit. Treating IP as a core commercial asset, reviewed and refreshed as the business evolves, protects both valuation and negotiating leverage.
Labour is also an important asset for companies, and it is important to get the right engagement classification and structure for the team from the beginning, whether that’s the founders, consultants, scientific advisory board members, business operational staff, etc.
Any issues or terminations can be a significant barrier to scale and have an adverse effect on investor appetite to fund. This is particularly important to businesses that look to scale globally, and they should ensure the right people governance frameworks are in place.
The Golden Triangle advantage, used deliberately
Cambridge does not operate in isolation. Its connectivity with London and Oxford, and the wider Golden Triangle, continues to shape investment flows into the region.
For companies seeking transatlantic capital or European strategic partnerships, proximity to London’s capital markets and professional services infrastructure, combined with Oxford and Cambridge’s research depth, is a genuine differentiator.
Companies that actively position themselves within that network, tend to find it easier to attract both UK and international investors.
This advantage is particularly pronounced in life sciences, given the concentration of specialist investors and translational funding within the cluster.
Preparing for exit from day one
The companies that achieve the strongest outcomes on exit are usually those that started preparing for it years earlier, often without realising it.
Acquirers, particularly US strategic buyers, look closely at the quality of a target’s corporate housekeeping: clean cap tables, properly documented IP ownership, robust employment and consultancy arrangements, and evidence of good governance.
Businesses that address these issues as they grow, rather than in the run-up to a transaction, minimise friction and maximise value when the right opportunity arrives.
Founders who think about the eventual buyer’s perspective from an early stage, rather than only once a term sheet is on the table, are consistently better positioned when that moment comes.
A full life cycle of support
From first funding round to global exit, Cambridge’s life sciences companies benefit from a deep and increasingly sophisticated regional ecosystem of investors, advisers and institutions.
As the cluster matures, the businesses that will go furthest are those that treat commercial discipline, from cap table hygiene to IP strategy, as a priority from the outset, not an afterthought.
For advisers working closely with this community, that means being involved early, with deep sector expertise, and staying close as companies scale; whilst also being able to support those companies, domestically and internationally, when later stage funding or exit conversations begin.
For regional businesses, that is an increasingly powerful message: companies no longer need to piece together support from multiple London-based advisers to scale globally, because that expertise now exists within the Cambridge ecosystem itself.
